PMID: 7082782Jan 1, 1982Paper

Comparison of gentamicin and tobramycin nephrotoxicity in patients receiving individualized-pharmacokinetic dosing regimens

Biopharmaceutics & Drug Disposition
S PancorboJ Heissler

Abstract

The incidence of nephrotoxicity has been studied in 175 patients who received either gentamicin or tobramycin. All patients received individualized dosing regimens of the drugs based on pharmacokinetic parameters measured after the initial dose. Subsequent doses were calculated from the pharmacokinetic data to produce peak aminoglycoside levels of between 6 and 8 micrograms ml-1 and trough levels that were below 2 micrograms ml-1. Renal toxicity was defined as a 30 per cent or greater increase in the serum creatinine level above the baseline value. Five of the 125 patients (4 per cent) who received gentamicin, and 1 of the 39 patients (2.6 per cent) who received tobramycin developed signs of nephrotoxicity. This difference was not statistically significant.

References

Sep 1, 1977·Clinical Pharmacology and Therapeutics·J J Schentag, W J Jusko
Aug 1, 1976·The Journal of Infectious Diseases·C L Bendush, R Weber
Oct 1, 1976·Archives of Internal Medicine·N E GaryR P Eisinger
Apr 1, 1976·Journal of Pharmacokinetics and Biopharmaceutics·R J Sawchuk, D E Zaske
Jul 1, 1975·Antimicrobial Agents and Chemotherapy·J G DahlgrenW L Hewitt
Dec 1, 1971·The Journal of Infectious Diseases·J N WilfertC R Smith
Dec 1, 1971·The Journal of Infectious Diseases·A M GyselynckR Cutler
May 15, 1980·The New England Journal of Medicine·C R SmithP S Lietman

Related Concepts

Antibiotics
Krebiozen
Drug Administration Schedule
Gentacycol
Kidney Diseases
Tobracin

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.